Pfizer (NYSE:PFE) Trading Down 2.3% - Here's Why

Key Points

• Pfizer's stock declined by 2.3% to close at $25.67, with a trading volume increase of 3% from its average.
• Analysts have mixed views on Pfizer, with ratings ranging from Strong Buy to Sell, while the consensus target price is $28.41.
• The company reported earnings of $0.78 per share for the last quarter, exceeding estimates, and expects an EPS guidance of 2.900-3.100 for FY 2025.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price traded down 2.3% during trading on Wednesday . The stock traded as low as $25.63 and last traded at $25.67. 48,015,668 shares were traded during mid-day trading, an increase of 3% from the average session volume of 46,804,590 shares. The stock had previously closed at $26.27.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Finally, Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $28.41.

Pfizer Price Performance

The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $145.95 billion, a PE ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The firm's fifty day simple moving average is $24.76 and its 200-day simple moving average is $24.14.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business earned $0.60 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of the business. Capital Advisory Group Advisory Services LLC boosted its stake in shares of Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 388 shares during the last quarter. Citizens National Bank Trust Department lifted its position in Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares in the last quarter. Peak Asset Management LLC lifted its position in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock valued at $697,000 after purchasing an additional 402 shares in the last quarter. Able Wealth Management LLC lifted its position in Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Finally, Boltwood Capital Management lifted its position in shares of Pfizer by 0.7% during the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company's stock valued at $1,485,000 after buying an additional 420 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.